64 related articles for article (PubMed ID: 38562545)
1. Fecal calprotectin in systemic sclerosis and review of the literature.
Marie I; Leroi AM; Menard JF; Levesque H; Quillard M; Ducrotte P
Autoimmun Rev; 2015 Jun; 14(6):547-54. PubMed ID: 25661980
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and predictors of small intestinal bacterial overgrowth in systemic sclerosis: a systematic review and meta-analysis.
Feng X; Li XQ; Jiang Z
Clin Rheumatol; 2021 Aug; 40(8):3039-3051. PubMed ID: 33426631
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of rifaximin in patients with chronic intestinal pseudo-obstruction: a randomized, double-blind, placebo-controlled, phase II-a exploratory trial.
Ohkubo H; Kessoku T; Tanaka K; Takahashi K; Takatsu T; Yoshihara T; Misawa N; Ashikari K; Fuyuki A; Kato S; Higurashi T; Hosono K; Yoneda M; Misumi T; Shinoda S; Stanghellini V; Nakajima A
Biosci Microbiota Food Health; 2024; 43(2):135-144. PubMed ID: 38562545
[TBL] [Abstract][Full Text] [Related]
4. Effect of Trimebutine and Rifaximin on Breath Hydrogen and Methane by Glucose Breath Test in Patients With Functional Bloating: A Randomized Double-blind Clinical Trial.
Jo IH; Paik CN; Lee JM; Song DS; Kim YJ
J Neurogastroenterol Motil; 2024 Apr; 30(2):220-228. PubMed ID: 38576371
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and treatment of small intestinal bacterial overgrowth in postoperative patients with colorectal cancer.
Deng L; Liu Y; Zhang D; Li Y; Xu L
Mol Clin Oncol; 2016 May; 4(5):883-887. PubMed ID: 27123301
[TBL] [Abstract][Full Text] [Related]
6. Berberine and rifaximin effects on small intestinal bacterial overgrowth: Study protocol for an investigator-initiated, double-arm, open-label, randomized clinical trial (BRIEF-SIBO study).
Guo H; Lu S; Zhang J; Chen C; Du Y; Wang K; Duan L
Front Pharmacol; 2023; 14():1121435. PubMed ID: 36873985
[No Abstract] [Full Text] [Related]
7. [Clinical features of irritable bowel syndrome with small intestinal bacterial overgrowth and a preliminary study of effectiveness of Rifaximin].
Liu ZJ; Wei H; Duan LP; Zhu SW; Zhang L; Wang K
Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(24):1896-902. PubMed ID: 27373356
[TBL] [Abstract][Full Text] [Related]
8. Small intestinal bacterial overgrowth in patients suffering from scleroderma: clinical effectiveness of its eradication.
Parodi A; Sessarego M; Greco A; Bazzica M; Filaci G; Setti M; Savarino E; Indiveri F; Savarino V; Ghio M
Am J Gastroenterol; 2008 May; 103(5):1257-62. PubMed ID: 18422815
[TBL] [Abstract][Full Text] [Related]
9. Natural History of Chronic Intestinal Pseudo-obstruction and Need for Palliative Care.
Tanaka K; Ohkubo H; Yamamoto A; Takahashi K; Kasai Y; Ozaki A; Iwaki M; Kobayashi T; Yoshihara T; Misawa N; Fuyuki A; Kato S; Higurashi T; Hosono K; Yoneda M; Kurihashi T; Taguri M; Nakajima A; Gwee KA; Kessoku T
J Neurogastroenterol Motil; 2023 Jul; 29(3):378-387. PubMed ID: 37417265
[TBL] [Abstract][Full Text] [Related]
10. Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial.
Kessoku T; Imajo K; Kobayashi T; Ozaki A; Iwaki M; Honda Y; Kato T; Ogawa Y; Tomeno W; Kato S; Higurashi T; Yoneda M; Kirikoshi H; Kubota K; Taguri M; Yamanaka T; Usuda H; Wada K; Kobayashi N; Saito S; Nakajima A
Lancet Gastroenterol Hepatol; 2020 Nov; 5(11):996-1007. PubMed ID: 32805205
[TBL] [Abstract][Full Text] [Related]
11. How Probiotics Affect the Microbiota.
Wieërs G; Belkhir L; Enaud R; Leclercq S; Philippart de Foy JM; Dequenne I; de Timary P; Cani PD
Front Cell Infect Microbiol; 2019; 9():454. PubMed ID: 32010640
[TBL] [Abstract][Full Text] [Related]
12. Role of Probiotics in Human Gut Microbiome-Associated Diseases.
Kim SK; Guevarra RB; Kim YT; Kwon J; Kim H; Cho JH; Kim HB; Lee JH
J Microbiol Biotechnol; 2019 Sep; 29(9):1335-1340. PubMed ID: 31434172
[TBL] [Abstract][Full Text] [Related]
13. Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation.
Ponziani FR; Zocco MA; D'Aversa F; Pompili M; Gasbarrini A
World J Gastroenterol; 2017 Jul; 23(25):4491-4499. PubMed ID: 28740337
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of percutaneous endoscopic gastro-jejunostomy (PEG-J) decompression therapy for patients with chronic intestinal pseudo-obstruction (CIPO).
Ohkubo H; Fuyuki A; Arimoto J; Higurashi T; Nonaka T; Inoh Y; Iida H; Inamori M; Kaneda T; Nakajima A
Neurogastroenterol Motil; 2017 Dec; 29(12):. PubMed ID: 28631871
[TBL] [Abstract][Full Text] [Related]
15. Lubiprostone improves intestinal permeability in humans, a novel therapy for the leaky gut: A prospective randomized pilot study in healthy volunteers.
Kato T; Honda Y; Kurita Y; Iwasaki A; Sato T; Kessoku T; Uchiyama S; Ogawa Y; Ohkubo H; Higurashi T; Yamanaka T; Usuda H; Wada K; Nakajima A
PLoS One; 2017; 12(4):e0175626. PubMed ID: 28410406
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
